Summary
Amgen Inc. (AMGN) has filed an 8-K report on July 9, 2009, to announce a key addition to its Board of Directors. The company appointed Rebecca M. Henderson as a new director, effective immediately. Dr. Henderson brings a wealth of expertise in technology strategy and the strategic challenges faced by high-tech industries, stemming from her faculty position at Harvard Business School and prior professorship at MIT. Her appointment is expected to enhance the company's strategic guidance. Dr. Henderson's compensation as a director includes a pro-rated annual retainer, meeting attendance fees, and expense reimbursements. Significantly, she will receive an initial grant of 20,000 stock options and will participate in the company's standard director equity incentive programs, including annual grants of restricted stock units and stock options. These equity awards are designed to align her interests with those of shareholders and are subject to vesting schedules based on her tenure.
Key Highlights
- 1Amgen appointed Rebecca M. Henderson to its Board of Directors, effective July 9, 2009.
- 2Dr. Henderson is a Professor at Harvard Business School with expertise in technology strategy.
- 3She previously served as a Professor at MIT Sloan School of Management.
- 4Dr. Henderson will serve on the Corporate Responsibility and Compliance Committee and the Governance and Nominating Committee.
- 5There are no disclosed conflicts of interest or related party transactions involving Dr. Henderson.
- 6Her compensation includes a pro-rated director retainer, meeting fees, and expense reimbursement.
- 7Dr. Henderson will receive an initial grant of 20,000 stock options and participate in the company's standard director equity incentive plans, including restricted stock units and additional stock options.